Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2018-001221-98-AT
EUCTR2018-001221-98-ATActive, not recruitingPhase 1

DEXAMETHASONE AS ADJUVANT FOR PERIPHERAL NERVE BLOCKADE: A RANDOMIZED, TRIPLE-BLINDED AND CROSSOVER STUDY IN VOLUNTEERS - Dexamethason adjuvant study

Medical University of Vienna, Department of Clinical Pharmacology0 sites24 target enrollmentStarted: May 14, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
24
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Inclusion Criteria

  • •Healthy males
  • •Healthy, according to the medical history, ECG, vital signs, laboratory results and physical examination as determined by the Investigator/Sub-Investigator
  • •Signed written informed consent prior to inclusion in the study
  • •18-55 years old inclusive
  • •Clearly detectable ulnar nerve at the non-dominant arm in ultrasound evaluation, according to the main investigators opinion (P.M.)
  • •BMI: 18 to 35 kg/m2
  • •Ability to understand the full nature and purpose of the study, including possible risks and side effects
  • •Ability to co-operate with the investigator and to comply with the requirements of the entire study
  • •Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 24
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •Any clinically relevant abnormalities at ECG (12 leads)
  • •Any clinically relevant abnormal physical findings
  • •Any clinically relevant abnormal laboratory values indicative of physical illness
  • •Ascertained or presumptive hypersensitivity to the active principle and/or formulations ingredients of the study drug
  • •History of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study
  • •If one of the investigated nerves are not clearly visible in ultrasound
  • •Relevant history of malignancy, of renal, hepatic, cardiovascular, respiratory, gastrointestinal, musculoskeletal, skin (particularly at the site of drug application), haematological, endocrine or neurological diseases that may interfere with the aim of the study
  • •Any psychiatric illnesses
  • •Using other medications during 1 week before the start of IMP application including OTC
  • •Participation in another clinical study investigating another IMP within 1 month prior to screening
  • •Blood donations during 4 weeks prior to this study History of drug or alcohol abuse (>2 drinks/day, defined according to USDA Dietary Guidelines 2015)
  • •Other objections to study participation in the opinion of the investigator

Investigators

Sponsor
Medical University of Vienna, Department of Clinical Pharmacology

Similar Trials

Not yet recruiting
Phase 2
DEXAMETHASONE AS ADJUVANT FOR PERIPHERAL NERVE BLOCKADE: A RANDOMIZED, TRIPLE-BLINDED AND CROSSOVER STUDY IN VOLUNTEERS- dexamethasone for peripheral nerve blocksHealthy volunteers
DRKS00014604Medizinische Universität Wien24
Active, not recruiting
Not Applicable
Dexmedetomidine (=Drug for Block Prolongation) used for Regionla Anaesthetic Blockade: A Dosefinding Study in Volunteers24 Volunteers recieve an ultrasound guided ulnar nerve block, and apparted into 4 groups. Group 1 receives 3ml Ropivacaine 0.75% without adjuvants. Group 2-4 receives 3ml Ropivacain 0.75% with three different doses of dexmedetomidine (50, 100,150 mcg). The aim of the study is to eveluate the optimal dose regarding sensory duration of nerve block without side effects of dexmedetomidine.
EUCTR2013-003790-10-ATMedizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
Completed
Not Applicable
HEADING TOWARDS BETTERMENT OF PAINLESS DELIVERY OF PREGNANT WOMEN.
CTRI/2018/09/015751A80
Not yet recruiting
Unknown
The effects of perineural dexamethasone as a adjunct to ropivacaine fascia iliaca block for hip fracture surgery; A Randomized Controlled Trial
KCT0008845Konyang University Hospital62
Active, not recruiting
Phase 1
Oral dexamethasone as an adjunct to a peripheral nerve block in patients undergoing surgery of the forearm and hand.
EUCTR2021-000428-36-DKZealand University Hospital, Department of Anaesthesiology180